Compare AstraZeneca plc (AZN) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Quanta Services Inc — how do they compare? AstraZeneca plc trades at $157.99 (market cap $248.14B), while Quanta Services Inc trades at $682.39 (market cap $100.82B). The key difference: AstraZeneca plc is far larger — about 2.5× Quanta Services Inc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | PWR | |
|---|---|---|
Market Cap | $248.14B | $100.82B |
Sector | Health | Industrials |
52-Week High | $209.48 | $785.24 |
52-Week Low | $147.06 | $372.50 |
Enterprise Value | $275.41B | $106.91B |
Dividend Yield | 2.01% | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
PWR trades at $660.86, down 1.64% over 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.24 versus $3.31 expected, and raised its full-year 2026 outlook. Revenue growth is robust, reaching $28.48B in 2025, though valuation ratios like a P/E of 76.73 appear elevated. Analyst sentiment is overwhelmingly positive, with 26 buy ratings and a consensus price target of $809.75.
The outlook for PWR is bullish, driven by record backlog and infrastructure demand, but high valuation and negative net cash flow pose risks. Investors face a trade-off between strong growth prospects and premium pricing, with execution on raised guidance being critical for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
